Insulin Therapy Center

New pen may improve glycemic control in people with severely insulin-resistant diabetes.

Knowing the stability of their insulin medications is key to patients’ ability to control their blood sugar levels. When should your patients dispose of their insulin if refrigerated, non-refrigerated, opened or still sealed? Print out this stability chart of vials and insulin pens to hand out to your patients. Insulin Stability …

Basal insulin peglispro, lacking peripheral action, was compared to insulin glargine in a 52-week trial in type 2 diabetic patients previously treated with basal insulin.

In assessing an in-patient's diabetic educational needs, I was reviewing with him his in-home regimen for his insulin therapy. Per his report, he stated that he took Levemir 50 units twice a day. I asked if it was by needle, syringe and vial preparation, which it was. I instructed him re: the shelf life of Levemir of 42 days once opened. He stated, "I throw it out after a month, but there is always insulin in the vial.” He also said he has more than an adequate supply. He was receiving his insulin by mail-order, receiving as he should, but not using it in a timely fashion. In other words, he was stockpiling his insulin.

Female, 28 years of age, diagnosed with type 1 diabetes at age 25. She was taught to manage her diabetes with a basal/bolus insulin regimen and meal plan prescribed by health care team. She was taught she could eat anything she wanted as long as she covered her carbs with rapid-acting insulin. Her glucose was in control, but she gained 50 pounds over the first year. She then attributed her weight gain to taking insulin, so she would not take enough insulin to cover her glucose levels.

Study finds insulin secretion returns to normal with one-gram fat loss.

In this week's Homerun Slides, the effect of dapagliflozin on endogenous glucose production, plasma insulin and glucagon concentration.

Diabetes in Control Publisher Steve Freed meets with Dr. Richard Bergman at the 75th ADA Scientific Sessions in Boston. In this first installment, Dr. Bergman shares his start in diabetes research and explains the high points of his presentation, Comparative Methods for Assessment of Insulin Sensitivity: Oral Vs. Intravenous. Dr. Richard Bergman is the founder and director of Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles. He introduced the use of engineering principles to understand the pathogenesis of diabetes.

Patients with highest fasting insulin had almost threefold higher risk of hypertension, left ventricular hypertrophy.

In this week's Homerun Slides, the addition of liraglutide to insulin degludec.